Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018,
More
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development
More
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin
More
